- Preparation and characterization of a new open-tubular capillary column for enantioseparation by capillary electrochromatography
-
In order to use the enantioseparation capability of cationic cyclodextrin and to combine the advantages of capillary electrochromatography (CEC) with open-tubular (OT) column, in this study, a new OT-CEC, coated with cationic cyclodextrin (1-allylimidazolium-β-cyclodextrin [AI-β-CD]) as chiral stationary phase (CSP), was prepared and applied for enantioseparation. Synthesized AI-β-CD was characterized by infrared (IR) spectrometry and mass spectrometry (MS). The preparation conditions for the AI-β-CD-coated column were optimized with the orthogonal experiment design L9(34). The column prepared was characterized by scanning electron microscopy (SEM) and elemental analysis (EA). The results showed that the thickness of stationary phase in the inner surface of the AI-β-CD-coated columns was about 0.2 to 0.5?μm. The AI-β-CD content in stationary phase based on the EA was approximately 2.77?mmol·m?2. The AI-β-CD-coated columns could separate all 14 chiral compounds (histidine, lysine, arginine, glutamate, aspartic acid, cysteine, serine, valine, isoleucine, phenylalanine, salbutamol, atenolol, ibuprofen, and napropamide) successfully in the study and exhibit excellent reproducibility and stability. We propose that the column, coated with AI-β-CD, has a great potential for enantioseparation in OT-CEC.
- Li, Yingjie,Tang, Yimin,Qin, Shili,Li, Xue,Dai, Qiang,Gao, Lidi
-
p. 283 - 292
(2019/02/05)
-
- Chromatographic Resolution of α-Amino Acids by (R)-(3,3'-Halogen Substituted-1,1'-binaphthyl)-20-crown-6 Stationary Phase in HPLC
-
Three new chiral stationary phases (CSPs) for high-performance liquid chromatography were prepared from R-(3,3'-halogen substituted-1,1'-binaphthyl)-20-crown-6 (halogen = Cl, Br and I). The experimental results showed that R-(3,3'-dibromo-1,1'-binaphthyl)-20-crown-6 (CSP-1) possesses more prominent enantioselectivity than the two other halogen-substituted crown ether derivatives. All twenty-one α-amino acids have different degrees of separation on R-(3,3'-dibromo-1,1'-binaphthyl)-20-crown-6-based CSP-1 at room temperature. The enantioselectivity of CSP-1 is also better than those of some commercial R-(1,1'-binaphthyl)-20-crown-6 derivatives. Both the separation factors (α) and the resolution (Rs) are better than those of commercial crown ether-based CSPs [CROWNPAK CR(+) from Daicel] under the same conditions for asparagine, threonine, proline, arginine, serine, histidine and valine, which cannot be separated by commercial CR(+). This study proves the commercial usefulness of the R-(3,3'-dibromo-1,1'-binaphthyl)-20-crown-6 chiral stationary phase.
- Wu, Peng,Wu, Yuping,Zhang, Junhui,Lu, Zhenyu,Zhang, Mei,Chen, Xuexian,Yuan, Liming
-
supporting information
p. 1037 - 1042
(2017/07/25)
-
- INSULIN PREPARATIONS CONTAINING METHIONINE
-
The invention relates to an aqueous pharmaceutical formulation having insulin, an insulin analog, or an insulin derivative, and methionine; and to the production thereof, to the use thereof for treating diabetes mellitus, and to a medication for treating diabetes mellitus.
- -
-
-
- ANTIBIOFILM GLYCOPEPTIDES
-
The present invention relates to peptides and compositions that have antibiofilm properties. In particular, the peptides and compositions of the invention can be used for the treatment or prevention of various conditions including dental caries, gingivitis, periodontitis, oral mucositis, dry mouth and xerostomia.
- -
-
-
- NOVEL INSULIN DERIVATIVES HAVING AN EXTREMELY DELAYED TIME-ACTION PROFILE
-
The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.
- -
-
-
- AGENT FOR PREVENTING/TREATING CANCER
-
A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an apoptosis inducer of cancer cells, a growth inhibitor of cancer cells, a cytotoxic agent against cancer cells through a host defense mechanism mediated by the Fc region of an antibody, and so on.
- -
-
-
- Modulation of Glutamine Synthetase Activity
-
Methods of screening and designing compounds as inhibitors of glutamine synthetase are provided herein. Compounds, e.g., serine protease inhibitors, and compositions comprising the same, that are useful for the treatment, prevention, and/or amelioration of bacterial infections, including Mycobacterium tuberculosis, are also provided.
- -
-
-
- NEUROMEDIN U DERIVATIVE
-
The objective of the present invention is to provide a new antifeedant. The other objective of the present invention is to provide a NMU derivative showing a high antifeedant activity even in common administration forms such as peripheral administration. A neuromedin U derivative wherein a methoxypolyethylene glycol is bound via a linker having a specific structure to a polypeptide which contains at least 8 amino acids of the C-terminus of an amino acid sequence of neuromedin U and which consists of the same or substantially the same amino acid sequence as the amino acid sequence of neuromedin U.
- -
-
-
- SOLUBILITY TAGS FOR THE EXPRESSION AND PURIFICATION OF BIOACTIVE PEPTIDES
-
Peptide tags, referred to here as inclusion body tags, are disclosed useful for the generation of insoluble fusion peptides. The fusion peptides comprise at least one inclusion body tag operably linked to a peptide of interest. Expression of the fusion peptide in a host cell results in a product that is insoluble and contained within inclusion bodies in the cell and/or cell lysate. The inclusion bodies may then be purified and the protein of interest may be isolated after cleavage from the inclusion body tag.
- -
-
-
- Compositions and Methods for Binding Lysophosphatidic Acid
-
Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described.
- -
-
-
- Preventive/Remedy for Cancer
-
A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an apoptosis inducer of cancer cells, a growth inhibitor of cancer cells, a cytotoxic agent against cancer cells through a host defense mechanism mediated by the Fc region of an antibody, and so on.
- -
-
-
- Chiral separation of underivatized amino acids by reactive extraction with palladium-BINAP complexes
-
(Figure Presented) In answer to the need for a more economic technology for the separation of racemates, a novel system for reactive enantioselective liquid-liquid extraction (ELLE) is introduced. Palladium (S)-BINAP complexes are employed as hosts in the separation of underivatized amino acids. The system shows the highest selectivity for the ELLE of tryptophan with metal complexes as hosts reported to date and shows a good selectivity toward a range of natural and unnatural amino acids. Furthermore, the host can be prepared in situ from commerically available compounds. Bulk-membrane transport in the form of U-tube experiments demonstrates the enantioselective and catalytic nature of the transport. The dependency of the system on parameters such as pH, organic solvent, and host-substrate ratio has been established. 31P NMR spectroscopy has been used to confirm the preferred enantiomer in the extraction experiments. The intrinsic selectivity was deduced by determination of the association constants of the palladium complex with the tryptophan enantiomers.
- Verkuijl, Bastiaan J. V.,Minnaard, Adriaan J.,De Vries, Johannes G.,Feringa, Ben L.
-
experimental part
p. 6526 - 6533
(2010/03/01)
-
- Cell adhesion and extracellular matrix proteins
-
Various embodiments of the invention provide human cell adhesion and extracellular matrix proteins (CADECM) and polynucleotides which identify and encode CADECM. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of CADECM.
- -
-
-
- HIGH-AFFINITY INTERLEUKIN-4 MUTEINS
-
A recombinant human IL-4 mutein numbered in accordance with wild-type IL-4 wherein the mutein comprises at least one amino acid substitution in the binding surface of either the A- or C-alpha helices of the wild-type IL-4 whereby the mutein binds to the IL-4R alpha receptor with at least greater affinity than native IL-4. The substitution is more preferably selected from the group of positions consisting of, in the A-helix, positions 13 and 16, and in the C-helix, positions 81 and 89. A most preferred embodiment is the recombinant human IL-4 mutein wherein the substitution at position 13 is Thr to Asp. Pharmaceutical compositions, amino acid and polynucleotide sequences encoding the muteins, transformed host cells, antibodies to the muteins, and methods of treatment are also described.
- -
-
-
- CIS-ELEMENT REGULATING TRANSCRIPTION, TRANSCRIPTIONAL REGULATORY FACTOR BINDING SPECIFICALLY THERETO AND USE OF THE SAME
-
The present invention provides a novel fructose responsive transcription control cis-element and a transcriptional regulatory factor that interacts therewith, a non-human animal having them transferred or inactivated, a diagnostic method for genetic susceptibility to a metabolic disorder using them, and a screening method for a prophylactic or therapeutic drug for a metabolic disorder using them.
- -
-
-
- Novel protein and use thereof
-
A novel gene likely inhibiting the onset and progress of cancer. A protein having an amino acid sequence which is the same or substantially the same as the amino acid sequence represented by SEQ ID NO:4 or its salt; a polynucleotide encoding the same; and medicinal use, etc. thereof are provided.
- -
-
-
- T-CELL SELECTIVE INTERLEUKIN-4 AGONISTS
-
The invention is directed to human IL-4 muteins numbered in accordance with wild-type IL-4 having T-cell activating activity, but having reduced endothelial cell activating activity. In particular, the invention is related to human IL-4 muteins wherein the surface-exposed residues of the D helix of the wild-type IL-4 are mutated whereby the resulting mutein causes T-cell proliferation, and causes reduced IL-6 secretion from HUVECs, relative to wild-type IL-4. This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of this interleukin. Further, the invention is directed to IL-4 muteins having single, double and triple mutations represented by the designators R121A, R121D, R121E, R121F, R121H, R121I, R121K, R121N, R121P, R121T, R121W; Y124A, Y124Q, Y124R, Y124S, Y124T; Y124A/S125A, T13D/R121E; and R121T/E122F/Y124Q, when numbered in accordance with wild-type IL-4 (His=1). The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
- -
-
-
- Insulin analogs with enhanced zinc binding
-
The invention relates to insulin analogs exhibiting enhanced zinc binding capacity and to stable zinc complexes thereof having a retarded activity in comparison with human insulin. The invention further relates to a method for the production of said insulin analogs and to their use, particularly in pharmaceutical preparations for therapy of type I and type II diabetes mellitus.
- -
-
-
- Alpha-glycated amino acid releasing enzyme
-
The present invention relates to a novel enzyme (α-GARE) which releases an amino acid residue having a glycated α-amino group (α-GA) from a glycated protein etc. and to bacterial strains producing the same. Examples of the bacterial strains include Sphingomonas parapaucimobilis KDK1004 (FERM BP-7041). The α-GARE is contained in the culture supernatant of this strain and α-GA can be released from a glycated peptide by using the same, as shown in FIG. 1.
- -
-
-
- Novel G protein-coupled receptor protein, its DNA and ligand thereof
-
The polypeptides in the present invention possess the effects of promoting and inhibiting the secretion of prolactin, and are thus useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion stimulants, which are associated with the secretion of prolactin, such as hypoovarianism, spermatic underdevelopment, menopausal symptoms, hypothyroidism, etc. The polypeptides are useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion inhibitors, which are associated with the secretion of prolactin, such as pituitary tumor, diencephalon tumor, menstrual disorder, autoimmune diseases, prolactinoma, sterility, impotence, amenorrhea, lactorrhea, acromegaly, Chiari-Frommel syndrome, Argonz-del Castilo syndrome, Forbes-Albright syndrome, lymphoma, Sheehan's syndrome, spermatogenesis disorder, etc.
- -
-
-
- Novel polypeptide and its dna
-
It is intended to construct a screening method, etc. for searching for compounds which are capable of binding to apolipoprotein A-I and thus promote or inhibit the binding of a cubulin fragment to apolipoprotein A-I, and provide preventives or remedies containing compounds obtained by the above screening method, etc. These compounds, etc. are usable in preventives and remedies for various diseases in which cubulin participates and the like.
- -
-
-
- T-cell selective interleukin-4 agonists
-
This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of interleukin 4. Further, the invention is directed to IL-4 muteins having single and double mutations represented by the designators R121E and T13D/R121E, numbered in accordance with wild type IL-4 (His=1). The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
- -
-
-
- Method of using PON-1 to decrease atheroma formation
-
The invention is directed to a method of decreasing atheroma formation in a mammal comprising administering a pharmaceutically effective amount of PON-1 or its functional equivalent to a patient in need thereof. Also included herein are pharmaceutical compositions, and a method for diagnosing predisposition to hypercholesterolemia by assessing the level of native circulating PON-1.
- -
-
-
- Green fluorescent protein fusions with random peptides
-
The invention relates to the use of fluorescent proteins, particularly green fluorescent protein (GFP), in fusion constructs with random and defined peptides and peptide libraries, to increase the cellular expression levels, decrease the cellular catabolism, increase the conformational stability relative to linear peptides, and to increase the steady state concentrations of the random peptides and random peptide library members expressed in cells for the purpose of detecting the presence of the peptides and screening random peptide libraries. N-terminal, C-terminal, dual N- and C-terminal and one or more internal fusions are all contemplated. Novel fusions utilizing self-binding peptides to create a conformationally stabilized fusion domain are also contemplated.
- -
-
-
- Methods of enhancing functioning of the large intestine
-
The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
- -
-
-
- Human betacellulin-specific antibodies and uses thereof
-
Disclosed are an antibody which have a binding activity to human betacellulin protein or a mutein thereof with specificity; especially a monoclonal antibody which does not have cross reactitivity with human epidermal growth factor (EGF) and human transforming growth factor a (TGF-α), belongs to the immunoglobulin class of IgG, and,specifically binds to human betacellulin protein to neutralize biological activity thereof; a hybridoma for producing the monoclonal antibody; and a method for producing the monoclonal antibody. Said monoclonal antibody neutralizes biological activity of a human BTC protein, and bind to the protein with high sensitivity and specificity, so that they can be used as a therapeutic agent for diseases such as arterial sclerosis and cancers, and also used as a reagent for assaying the human BTC protein or a mutein thereof and as a diagnostic agent for diabetes or complications thereof.
- -
-
-
- Methods of enhancing functioning of the upper gastrointestinal tract
-
The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the upper gastrointestinal tract including the esophagus and stomach. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of the upper gastrointestinal tract. Thus, the invention provides methods of proliferating the upper gastrointestinal tract in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the upper gastrointestinal tract, including inflammatory diseases. GLP-2 stimulates the growth of upper gastrointestinal tissue when administered in conjunction with other peptide hormones. The invention further provides pharmaceutical compositions of GLP-2 with at least one other peptide hormone, methods of enhancing the growth of upper gastrointestinal tissue and of gastrointestinal disorders by increasing serum levels of GLP-2 and at least one other peptide hormone, and kits for preforming the methods of the invention.
- -
-
-
- Method of producing a 19P2 ligand
-
The method of the present invention is suitable for the commercial high-level production of a protein or peptide which can be used as a prophylactic and therapeutic drug for various diseases such as senile dementia, cerebrovascular dementia (dementia arising from cerebrovascular disorders), dementia associated with genealogical retroplastic diseases (e.g. Alzheimer's disease, Parkinson's disease, Pick's disease, Huntington's disease, etc.), dementia associated with infectious diseases (e.g. Creutzfeldt-Jakob's and other virus diseases), dementia associated with endocrine or metabolic disease or toxicosis (e.g. hypothyroidism, vitamin B12 deficiency, alcoholism, intoxication by drugs, metals, and organic compounds), dementia associated with tumorigenic diseases (e.g. brain tumor), dementia associated with traumatic diseases (e.g. chronic subarachnoidal hemorrhage), and other types of dementia, depression, hyperactive child syndrome (microencephalopathy), and disturbance of consciousness. Additionally, the ligand polypeptide of the present invention has prolactin secretion-stimulating and inhibiting activities.
- -
-
-
- High-affinity interleukin-4 muteins
-
This invention is directed to recombinant human IL-4 muteins numbered in accordance with wild-type IL-4 wherein the muteins comprise at least one amino acid substitution selected from the group consisting of substitutions at positions 13, 16, 81 and 89 of the wild-type IL-4, whereby the mutein binds to the IL-4R alpha receptor with at least greater affinity than native IL-4. The invention is further directed to recombinant human IL-4 antagonist muteins numbered in accordance with wild-type IL-4 wherein the muteins comprise substitutions R121D and Y124D in the D-helix of said wild-type IL-4; and at least one amino acid substitution selected from the group consisting of substitutions at positions 13, 16, 81 and 89 of said wild-type IL-4, whereby the mutein binds to the IL-4R alpha receptor with at least greater affinity than native IL-4. The invention is also directed to pharmaceutical compositions comprising individual muteins in combination with pharmaceutically acceptable carriers.
- -
-
-
- Human CRM1 Protein
-
A protein which comprises the sane or substantially the same amino acid sequence as that represented by SEQ ID NO:1, its partial peptide and their salts are disclosed. DNA encoding the protein or its partial peptide is also disclosed. The protein, its partial peptide or a salt thereof is an inhibitory factor of a transcription factor and, therefore, it is useful as medicine such as prophylactic and therapeutic drugs of, for example, tumors. The DNA is useful as a gene diagnosing drug. The antibody against the protein, etc. is also disclosed. The antibody is used for, for example, quantitative determination of the protein, etc. in a specimen fluid. The protein, etc. are also useful as a reagent for screening for compounds or their salts which promote the function of the protein, etc.
- -
-
-
- Modification of pertussis toxin
-
The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.
- -
-
-
- T-cell selective interleukin-4 agonists
-
The invention is directed to human IL-4 muteins numbered in accordance with wild-type IL-4 having T cell activating activity, but having reduced endothelial cell activating activity. In particular, the invention is related to human IL-4 muteins wherein the surface-exposed residues of the D helix of the wild-type IL-4 are mutated whereby the resulting mutein causes T cell proliferation, and causes reduced IL-6 secretion from HUVECs, relative to wild-type IL-4. This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of this interleukin. Further, the invention is directed to IL-4 muteins having single, double and triple mutations represented by the designators R121A, R121D, R121E, R121F, R121H, R1211, R121K, R121N, R121P, R121T, R121W; Y124A, Y124Q, Y124R, Y124S, Y124T; Y124A/S125A, T13D/R121E; and R121T/E122F/Y124Q, when numbered in accordance with wild type IL-4 (His=1). The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
- -
-
-
- PEPTIDE LIGANDS FOR AFFINITY PURIFICATION OF HUMAN FACTOR VIII
-
Peptides which bind Factor VIII are disclosed. The peptides have available Factor VIII binding domains having a Trp-His-Tyr-Tyr-His-Gly, His-Ile-Gln-His-Tyr-His, or His-Gln-Tyr-Gly-Tyr-His sequence. Peptides having at least one of these Factor VIII binding domains are immobilized upon a chromatographic substrate in a preferred embodiment of the invention. This preferred embodiment is useful in a chromatography process to purify human Factor VIII.
- -
-
-
- Cloning and production of human von Willebrand Factor GP1b binding domain polypeptides and methods of using same
-
The subject invention provides non-glycosylated, biologically active polypeptides which comprise the vWF (van Willebrand Factor) GP1b binding domain. These polypeptides may be used to inhibit platelet adhesion and aggregation in the treatment of subjects with conditions such as cerebrovascular disorders and cardiovascular disorders. This invention also provides expression plasmids encoding these polypeptides as well as methods of producing by transforming a bacterial cell and recovering such polypeptides. In addition, the subject invention provides methods of treating and preventing cerebrovascular, cardiovascular and other disorders using these polypeptides to inhibit platelet aggregation.
- -
-
-
- Reduction potential of histidine free radicals: A pulse radiolysis study
-
The technique of pulse radiolysis has been used to demonstrate that all histidine free radicals (designated His.+) produced by oxidation of histidine by Br2.- radical anions can oxidise the water soluble vitamin E analogue, Trolox C (k = 1.0 ± 0.2 × 109 dm3 mol-1 s-1 at pH 6.95). It has also been shown that His.+ radicals can react with tryptophan in electron transfer equilibria involving both His.+ and Trp.+ species over the pH range 6.4-9.0. The ΔE values [E(Trp.+/Trp) - E(His.+/His)] range from -140 to -161 mV and indicate an E7(His.+/His) value of 1170 mV [based on E7(Trp.+/Trp) = 1015 mV at pH 7]. The effect of pH on E(His.+/His) was accounted for by assuming that His.+ can deprotonate to yield a bi-allylic free radical, designated His (-H+).. The pKa for this dissociation was estimated to be in the range 5-7. The implications of the relatively high reduction potential for His.+ in its possible participation in the mechanism of action of non-heme metalloenzymes is discussed.
- Navaratnam,Parsons
-
p. 2577 - 2581
(2007/10/03)
-
- Hst-2 muteins, pharmaceutical compositions and kits comprising same, and preparation of same
-
The present invention provides a polypeptide represented by the following amino acid sequence: STR1 wherein n is 0 or 1 and X represents Pro Ala Gly Thr Arg Ala Asn Asn Thr Leu Leu Asp Ser Arg Gly Trp Gly Thr Leu Leu Ser Arg Ser Arg Ala Gly or a fragment thereof (n=0: SEQ ID NO:1, n=1: SEQ ID NO:2), a recombinant DNA coding for the polypeptide, a vector containing the recombinant DNA, the preparation of a transformant carrying the vector, and the production of the polypeptide with the transformant. The use of this peptide in pharmaceutical compositions is also provided.
- -
-
-
- Synthetic calcitonin mimetics
-
The invention provides synthetic calcitonin mimetics. The mimetics of the present invention may include modifications that further enhance desired characteristics, such as oral bioavailability, while maintaining or enhancing inhibition of bone resorption. Related pharmaceutical compositions and methods are also disclosed.
- -
-
-
- Monoclonal antibodies to PACAP
-
Disclosed are a monoclonal antibody having affinity for PACAP, a partial peptide thereof, a precursor thereof or VIP; a hybridoma cell which produces the above monoclonal antibody; and an immunoassay for assaying PACAP by a competitive method or a sandwich method using the above antibody, whereby PACAP can be specifically detected with high sensitivity.
- -
-
-
- Muteins of IFN-β
-
A IFN-β mutein in which phe (F), tyr (Y), trp (W) or his (H) is substituted for val (V) at position 101, when numbered in accordance with wild type IFN-β, DNA sequences encoding these IFN-β muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an IFN-β mutein, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing IFN-β muteins and methods of using those compositions to treat viral infections, cancer or tumors or for immunomodulation.
- -
-
-
- N-terminally truncated hst-1 is a platelet-increasing factor
-
A method of increasing platelets in mammals which comprises administering to mammals an effective amount of a heparin-binding secretory transforming factor 1 protein (hst-1) having an N-terminal deletion of 27 amino acids.
- -
-
-
- Modified GAF polypeptides
-
The present invention relates to a glia activating factor (GAF) in which 33 to 49 N-terminal amino acids are deleted from the N-terminus of the GAF polypeptide of SEQ ID NO: 3, as well as an anti-GAF antibody which is highly sensitive to assay the GAF and is capable of neutralizing GAF's activity, is produced. Using the antibody, GAF and its biological activity can be assayed easily with high sensitivity. Further, the neutralizing antibody can be expected to have preventive and curative effects on diseases caused by GAF's excessive action. Furthermore, the GAF polypeptide disclosed herein is more stable to acids and heat than the conventional GAFs, therefore, it can be used as a platelet-increasing agent, etc., more advantageously than the previously known GAFs.
- -
-
-
- Peptides, analogues and mixtures thereof for detecting and eliciting antibodies to the E1 and E2 protein of rubella virus
-
This invention discloses linear and cyclic peptides of the E1 and E2 glycoproteins of the rubella virus. These peptides and analogues, mixtures and combinations of them are useful in detecting and quantifying antibodies raised against the rubella virus. They are also useful in raising antibodies to the rubella virus for use in the diagnosis of and protection against rubella viral infections.
- -
-
-
- Glycosylated FGF
-
Disclosed are (1) a mutein of a fibroblast growth factor (FGF), the DNA having introduced therein at least one nucleotide sequence coding for a glycosylation site, (2) a DNA coding for the mutein of (1), (3) a vector containing the DNA of (2), (4) a transformant transformed with the vector of (3), and (5) a process for producing the mutein which comprises cultivating in a culture medium the transformant of a yeast or animal cell transformed with a vector of (3), and producing and accumulating the mutein of (1) in the culture medium, whereby the FGF mutein into which at least one glycosylation site has been introduced is improved in productivity, stability and activities, and advantageously used as medicine.
- -
-
-
- LINEAR AND MONOCYCLIC ENDOTHELIN ANTAGONISTS
-
Novel linear and monocyclic antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling hypertension, myocardial infarction, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute renal failure, preeclampsia, and diabetes.
- -
-
-
- Monoclonal antibody to endothelin-3 or precursor thereof and use thereof
-
Disclosed are monoclonal antibodies having an affinity for endothelin-3 or a precursor thereof; a hybridoma cell which produces the monoclonal antibody; and an immunoassay of endothelin-3 and big endothelin-3, a precursor of endothelin-3, by a sandwich method or a competitive method. The monoclonal antibodies can be used as strong antagonists for endothelin-3 in various endothelin-3-related diseases, and the immunoassays make it possible to determine endothelin-3 and big endothelin-3 with high sensitivity.
- -
-
-
- Anti-thrombotic peptides and pseudopeptides
-
Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof containing certain amino acids and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.
- -
-
-
- Facile Production of D-Histidine by Asymmetric Transformation of L-Histidine
-
An asymmetric transformation from L-histidine to D-His was achieved by using salicylaldehyde as a catalyst for epimerization, and (2R,3R)-tartaric acid as a resolving agent, in acetic acid.Treatment of the obtained salt with triethylamine in methanol gave D-His with 100percent optical purity in 95percent yield based on the starting L-His.
- Shiraiwa, Tadashi,Shinjo, Kazuyuki,Masui, Yoko,Ohta, Atsushi,Natsuyama, Hisashi,et. al.
-
p. 3741 - 3742
(2007/10/02)
-
- Monoclonal antibody reacting with TRF (interleukin-5)
-
Disclosed is a monoclonal antibody having an ability to react with a lymphokine having a TRF-activity and having an ability, upon binding, to inhibit the TRF-activity of the lymphokine. The monoclonal antibody of this invention does not inhibit the activities of B cell stimulatory factor 1 (BSF-1), interleukin 1 (IL-1), interleukin 2 (IL-2), and interleukin 3 (IL-3). An immunoglobulin class identified by the means of Ouchterlony method is IgG1. The monoclonal antibody of this invention can be produced such that fused cells between proper cells (e.g., spleen cells prepared from a mammal) immunized with TRF and other proper cells (e.g., mouse myeloma cells) having large proliferation potential are cloned, and the fused cells are cultivated in vivo or in vitro. The monoclonal antibody of this invention is effective as an immunoadsorbent for the TRF or an inhibitor of the TRF-activity.
- -
-
-
- Amino-acid composition, method for its production and medical composition containing it
-
An amino acid composition comprising a specified amino acid sequence, showing a molecualr weight of 16,000 to 20,000 daltons upon SDS-polyacrylamide gel electrophoresis and 30,000 to 45,000 daltons upon gel filtration, and showing a specific activity of 0.5 x 109 to 3 x 109 units/mg protein. The amino acid composition exhibits an anti-tumor activity without injuring normal cells. A process of producing the amino acid composition via gene recombination technique and medical compositions thereof are also disclosed.
- -
-
-